Full text is available at the source.
Abstract
Antisense oligonucleotides (ASOs) may represent a new class of antibacterials, termed ASOBiotics, designed to silence essential bacterial genes.
- RNA-therapeutics have demonstrated clinical potential, particularly highlighted by mRNA vaccines during the COVID-19 pandemic.
- ASOs bind to specific mRNA sequences, leading to degradation or inhibition of protein translation in bacteria.
- Originally created for genetic and neurodegenerative disorders, ASOs are being repurposed for bacterial infection treatment.
- The design of ASOBiotics involves careful consideration of the bacterial targets and delivery mechanisms.
- Challenges and opportunities exist in developing precision antibacterial therapeutics using ASO technologies.
Simplified